Current prevention and potential treatment options for dengue infection

Malina Jasamai, Wei Boon Yap, Aurapa Sakulpanich, Azmath Jaleel

Research output: Contribution to journalArticle

Abstract

Currently, treatments for dengue infection are only symptomatic as no antiviral agents nor vaccines are available to combat this virus. Despite challenges faced by researchers, many efforts are ongoing to reduce cases of dengue infection either by targeting the vector or the virus. Vector population is monitored and reduced by using mechanical, chemical and biological controls. Chemical control is achieved either by using synthetic or natural insecticides where the latter is more preferable. In biological control, bacteria, fungi and larvivorous fish are utilised to reduce the vector population. Moreover, genes of mosquitoes are also explored to produce progenies which are sterile with low survival ability. Vaccines are among the most effective ways to prevent viral infection. Various approaches have been used and are still being explored towards producing vaccines for dengue. These include live attenuated, inactivated, recombinant subunit, nucleic acid and virus-like particles vaccines. The aim is to produce a vaccine which can target all the four serotypes of the virus. Monoclonal antibodies are widely researched on to equip the host defense mechanism against the dengue virus. Deeper understanding of the virus replication cycle warrants the development of antiviral agents which target viral proteins vital for the replication process. Bioactive compounds are also utilised in the development of antiviral agents. The importance of surveillance and supportive therapy are also discussed.

Original languageEnglish
Pages (from-to)440-456
Number of pages17
JournalJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
Volume22
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Dengue
Antiviral Agents
Vaccines
Viruses
Virus-Like Particle Vaccines
Dengue Vaccines
Infection
Dengue Virus
Viral Proteins
Virus Diseases
Virus Replication
Insecticides
Culicidae
Nucleic Acids
Population
Fishes
Fungi
Monoclonal Antibodies
Research Personnel
Bacteria

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

@article{7a8bb76eed654af9aee9adbfd1939e06,
title = "Current prevention and potential treatment options for dengue infection",
abstract = "Currently, treatments for dengue infection are only symptomatic as no antiviral agents nor vaccines are available to combat this virus. Despite challenges faced by researchers, many efforts are ongoing to reduce cases of dengue infection either by targeting the vector or the virus. Vector population is monitored and reduced by using mechanical, chemical and biological controls. Chemical control is achieved either by using synthetic or natural insecticides where the latter is more preferable. In biological control, bacteria, fungi and larvivorous fish are utilised to reduce the vector population. Moreover, genes of mosquitoes are also explored to produce progenies which are sterile with low survival ability. Vaccines are among the most effective ways to prevent viral infection. Various approaches have been used and are still being explored towards producing vaccines for dengue. These include live attenuated, inactivated, recombinant subunit, nucleic acid and virus-like particles vaccines. The aim is to produce a vaccine which can target all the four serotypes of the virus. Monoclonal antibodies are widely researched on to equip the host defense mechanism against the dengue virus. Deeper understanding of the virus replication cycle warrants the development of antiviral agents which target viral proteins vital for the replication process. Bioactive compounds are also utilised in the development of antiviral agents. The importance of surveillance and supportive therapy are also discussed.",
author = "Malina Jasamai and Yap, {Wei Boon} and Aurapa Sakulpanich and Azmath Jaleel",
year = "2019",
month = "1",
day = "1",
doi = "10.18433/jpps30216",
language = "English",
volume = "22",
pages = "440--456",
journal = "Journal of Pharmacy and Pharmaceutical Sciences",
issn = "1482-1826",
publisher = "Canadian Society for Pharmaceutical Sciences",
number = "1",

}

TY - JOUR

T1 - Current prevention and potential treatment options for dengue infection

AU - Jasamai, Malina

AU - Yap, Wei Boon

AU - Sakulpanich, Aurapa

AU - Jaleel, Azmath

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Currently, treatments for dengue infection are only symptomatic as no antiviral agents nor vaccines are available to combat this virus. Despite challenges faced by researchers, many efforts are ongoing to reduce cases of dengue infection either by targeting the vector or the virus. Vector population is monitored and reduced by using mechanical, chemical and biological controls. Chemical control is achieved either by using synthetic or natural insecticides where the latter is more preferable. In biological control, bacteria, fungi and larvivorous fish are utilised to reduce the vector population. Moreover, genes of mosquitoes are also explored to produce progenies which are sterile with low survival ability. Vaccines are among the most effective ways to prevent viral infection. Various approaches have been used and are still being explored towards producing vaccines for dengue. These include live attenuated, inactivated, recombinant subunit, nucleic acid and virus-like particles vaccines. The aim is to produce a vaccine which can target all the four serotypes of the virus. Monoclonal antibodies are widely researched on to equip the host defense mechanism against the dengue virus. Deeper understanding of the virus replication cycle warrants the development of antiviral agents which target viral proteins vital for the replication process. Bioactive compounds are also utilised in the development of antiviral agents. The importance of surveillance and supportive therapy are also discussed.

AB - Currently, treatments for dengue infection are only symptomatic as no antiviral agents nor vaccines are available to combat this virus. Despite challenges faced by researchers, many efforts are ongoing to reduce cases of dengue infection either by targeting the vector or the virus. Vector population is monitored and reduced by using mechanical, chemical and biological controls. Chemical control is achieved either by using synthetic or natural insecticides where the latter is more preferable. In biological control, bacteria, fungi and larvivorous fish are utilised to reduce the vector population. Moreover, genes of mosquitoes are also explored to produce progenies which are sterile with low survival ability. Vaccines are among the most effective ways to prevent viral infection. Various approaches have been used and are still being explored towards producing vaccines for dengue. These include live attenuated, inactivated, recombinant subunit, nucleic acid and virus-like particles vaccines. The aim is to produce a vaccine which can target all the four serotypes of the virus. Monoclonal antibodies are widely researched on to equip the host defense mechanism against the dengue virus. Deeper understanding of the virus replication cycle warrants the development of antiviral agents which target viral proteins vital for the replication process. Bioactive compounds are also utilised in the development of antiviral agents. The importance of surveillance and supportive therapy are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=85072516422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072516422&partnerID=8YFLogxK

U2 - 10.18433/jpps30216

DO - 10.18433/jpps30216

M3 - Article

C2 - 31539321

AN - SCOPUS:85072516422

VL - 22

SP - 440

EP - 456

JO - Journal of Pharmacy and Pharmaceutical Sciences

JF - Journal of Pharmacy and Pharmaceutical Sciences

SN - 1482-1826

IS - 1

ER -